Pretax income is the income that a company earns before paying income taxes. DiaMedica Therapeutics's pretax income for the
three
months ended in Mar. 2024 was $-5.14 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was $-19.22 Mil.
DiaMedica Therapeutics's pretax margin was %.
During the past 13 years, DiaMedica Therapeutics's highest Pretax Margin was -1130.80%. The lowest was -1130.80%. And the median was -1130.80%.
DiaMedica Therapeutics Pre-Tax Income Historical Data
The historical data trend for DiaMedica Therapeutics's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of DiaMedica Therapeutics's Pre-Tax Income
For the Biotechnology subindustry, DiaMedica Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DiaMedica Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DiaMedica Therapeutics's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where DiaMedica Therapeutics's Pre-Tax Income falls into.
DiaMedica Therapeutics Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
DiaMedica Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-19.22 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DiaMedica Therapeutics (NAS:DMAC) Pre-Tax Income Explanation
DiaMedica Therapeutics's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as
During the past 13 years, DiaMedica Therapeutics's highest Pretax Margin was -1130.80%. The lowest was -1130.80%. And the median was -1130.80%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DiaMedica Therapeutics Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of DiaMedica Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
DiaMedica Therapeutics (DiaMedica Therapeutics) Business Description
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DMAC has been successfully added to your 